



7th Annual
Innovative Approaches to
Brain Tumor Management

Friday, February 11, 2022

Syllabus

ESTEEMED FACULTY

Charles Cobbs, M.D.

Course Co-Chair

Director, Ben & Catherine Ivy Center
Swedish Neuroscience Institute
Seattle, Washington

Kester Phillips, M.D.

Course Co-Chair

Neuro-oncologist
Ben & Catherine Ivy Center
Seattle, Washington

Zachary N. Litvack, M.D., FAANS, FACS

Course Co-Chair

Director, Skull Base & Minimally Invasive Neurosurgery
Swedish Neuroscience Institute
Seattle, Washington

Matthew Smith-Cohn, D.O.

Course Co-Chair

Neuro-oncologist
Ben & Catherine Ivy Center
Seattle, Washington

Daniel Brown, M.D., MBA

Chair, Department of Pathology & Laboratory Medicine
Chief, Section of Neuropathology
Medical Director HNL Lab Medicine
Lehigh Valley Health Network
Allentown, PA

Howard Colman, M.D., Ph.D.

Leader of Center for Neurologic Cancer
Huntsman Cancer Institute
Salt Lake City, Utah

Lia Moriguchi Halasz, M.D.

Associate Professor, Department of Radiation Oncology
University of Washington School of Medicine
Physician, UW Medicine & Seattle Cancer Care Alliance
Seattle, Washington

Jim Heath, Ph.D.

President
Institute Systems Biology
Seattle, Washington

Parvinder Hothi, Ph.D.

Head Lab Scientist
Ben & Catherine Ivy Center
Swedish Neuroscience Institute
Seattle, Washington

David Olayinka Kamson, M.D., Ph.D.

Assistant Professor of Neurology
Department of Neuro-Oncology
Johns Hopkins Medicine
Baltimore, Maryland

Michael Lim, M.D.

Chair of Neurosurgery
Stanford Hospital
Palo Alto, California

Joe Mendez, M.D.

Assistant Professor of Neurosurgery
University of Utah & Huntsman Cancer Institute
Salt Lake City, Utah

Alon Orlev, M.D.

Neurosurgery Fellow
Swedish Neuroscience Institute
Seattle, Washington

Carlos Guillermo Romo, M.D.

Assistant Professor of Neurology
Johns Hopkins Hospital
Baltimore, Maryland

Akanksha Sharma, M.D.

Assistant Professor Neuro-Oncology Translational
Neurosciences
Providence Saint John's Health Center
Santa Monica, California

Karisa Shreck, M.D., Ph.D.

Assistant Professor of Neurology
The Johns Hopkins Hospital
Baltimore, Maryland

AGENDA

- 7:55 a.m. Welcome & Announcements**
Zachary N. Litvack, M.D. & Kester Phillips, M.D.
- 8 a.m. Advances in The Diagnosis, Evaluation, and Systemic Management of Leptomeningeal Metastasis**
Kester Phillips, M.D.
Objectives:
- Identify the pathophysiology and clinical manifestation of leptomeningeal metastasis
 - Identify emerging diagnostic tools for leptomeningeal metastasis
 - Identify emerging systemic therapeutic options for leptomeningeal carcinomatosis
- 8:15 a.m. Q&A**
- 8:20 a.m. Transiently Opening the Blood-Brain Barrier to Treat Malignancies: Challenges and Opportunities**
Matthew Smith-Cohn, D.O.
Objectives:
- Outline the challenges the blood-brain barrier poses in treating primary and secondary malignancies to the brain
 - Review treatment approaches being studied to transiently open the blood-brain barrier to increase drug delivery
- 8:35 a.m. Q&A**
- 8:40 a.m. Molecular Evaluation & Treatment of Gliomas**
Howard Colman, M.D.
Objectives:
- Identify and apply recent changes in glioma molecular characterization based on cIMPACT and WHO 2021 criteria
 - Describe the relationship between integrated histological/molecular diagnosis and appropriate therapy for gliomas
- 8:55 a.m. Q&A**
- 9 a.m. What's New in Surgery for Glioma?**
Alon Orlev, M.D.
Objectives:
- Outline latest evidence guiding surgical intervention for brain tumors
 - Describe when surgery is and is not indicated for primary or recurrent brain tumors
 - Identify alternatives and adjuncts to resection
- 9:15 a.m. Q&A**
- 9:20 a.m. Update of Imaging in Brain Tumors**
David Olayinka Kamson, M.D., Ph.D.
Objectives:
- Outline ongoing imaging harmonization efforts
 - Describe new interpretations for old imaging techniques
 - Summarize novel experimental imaging approaches
- 9:35 a.m. Q&A**

- 9:40 a.m. Clinical and Molecular Determinants of Outcome for Non-Optic Pathway Gliomas in Adults with Neurofibromatosis Type 1**
Carlos Guillermo Romo, M.D.
Objectives:
- Outline the difference in clinical and molecular features of gliomas in people with NF1 compared to sporadic cases
 - Identify the treatment options and outcomes for adults with NF1 and a non-optic pathway glioma
- 9:55 a.m. Q&A**
- 10 a.m. Update on Immunotherapy of Gliomas**
Michael Lim, M.D.
Objectives:
- Describe the current state of immunotherapy for brain tumors
 - Identify the strategies to overcome glioma induced immunosuppression
- 10:15 a.m. Q&A**
- 10:20 A.M. Digital Spatial Profiling of GBM and Melanoma Tumors Treated with Neuroadjuvant Checkpoint**
Jim Heath, Ph.D.
Objectives:
- Outline how the cellular microenvironment of the tumor can be characterized
 - Describe how that characterization provides hypotheses for drug targets
 - Identify major differences between the microenvironment of melanoma tumors relative to GBM tumors
- 10:35 a.m. Q&A**
- 10:40 a.m. Targeting Cancer Stem Cells for Treatment of Glioblastoma (*pre-recorded*)**
Parvinder Hothi, Ph.D.
Objectives:
- Outline the role of cancer stem-like cells in glioblastomas
 - Outline the methods for culturing and viable storage of tumor stem cells
 - Explain the use of high-throughput drug screening in devising personalized treatments
- 10:55 a.m. Q&A**
- 11 a.m. Incorporation of BRAF–Targeted Therapy into Neuro-Oncology Clinical Practice**
Karisa Schreck, M.D.
Objectives:
- Recognize molecular alterations for which BRAF–targeted therapy might be efficacious
 - Identify appropriate small molecule targeted therapy of clinical trials for an individual patient
 - Recognize toxicities of RAF–targeted therapy
- 11:15 a.m. Q&A**
- 11:20 a.m. Innovative Translational Research for Glioblastoma at The Ivy Center at Swedish Neuroscience Institute**
Charles Cobbs, M.D.
Objectives:
- Identify critical issues related to immunotherapy for glioblastoma
 - Identify key molecules for enhancing/targeting immunotherapy for glioblastoma
- 11:35 a.m. Q&A**
- 11:40 a.m. Primary CNS Lymphoma: An Overview of Management & Highlight of Advances**
Joe Mendez, M.D.

Objectives:

- Describe the initial evaluation/work-up of a patient with suspected newly diagnosed Primary CNS Lymphoma (PCNSL)
- Identify how to outline the work up to evaluate for the extent of CNS involvement and for systemic involvement
- Identify familiarities with the commonly used induction and consolidation therapies used to treat PCNSL

11:55 a.m. Q&A

12 p.m. The 2021 WHO Classification of Tumors of the CNS

Daniel Brown, M.D., MBA

Objectives:

- Outline both the major general changes as well as the specific changes in the more common taxonomic tumor categories
- Recognize the developments that are advancing the role of molecular diagnostics in CNS tumor classification
- Recognize shifting approaches to CNS nomenclature and grading emphasizing the importance of integrated diagnoses and layered reports

12:30 p.m. Q&A

12:35 p.m. Proton Therapy for Leptomeningeal Disease

Lia Moriguchi Halasz, M.D.

Objectives:

- Explain how proton therapy may improve the therapeutic index for patients with leptomeningeal disease
- Examine published data on craniospinal irradiation for leptomeningeal metastases
- Describe future directions in proton therapy for leptomeningeal disease

12:50 p.m. Q&A

12:55 p.m. Survivorship Care in Neuro-Oncology

Akanksha Sharma, M.D.

Objectives:

- Describe the importance of survivorship care for patients with brain tumors and their loved ones, emphasizing its unique place in cancer care
- Explain the key areas of importance as it applies to survivorship care for this patient population and the existing evidence on management for each
- Identify existing models of survivorship programs in neuro-oncology and a potential framework for the development of these programs at brain tumor centers

1:10 p.m. Q&A

1:15 p.m. Adjourn

Acknowledgements

The Planning Committee gratefully acknowledges support for this conference from

Educational Grant

Day Surgical
Integra LifeSciences
Novocure
NW Biotherapeutics

Exhibit Support

Novocure, Inc.
UCB

Course Planning Committee

Charles Cobbs, M.D.

Course Co-Chair
Director, Ben & Catherine Ivy Center
Swedish Neuroscience Institute
Seattle, Washington

Zachary N. Litvack, M.D.

Course Co-Chair
Director, Skull Base & Minimally Invasive Neurosurgery
Swedish Neuroscience Institute
Seattle, Washington

Kester Phillips, M.D.

Course Co-Chair
Neuro-oncologist
Ben & Catherine Ivy Center
Seattle, Washington

Matthew Smith-Cohn, D.O.

Course Co-Chair
Neuro-oncologist
Ben & Catherine Ivy Center
Seattle, Washington

Alon Orlev, M.D.

Neurosurgery Fellow
Swedish Neuroscience Institute
Seattle, Washington

Linda Sahlin

Director of Education
Seattle Science Foundation
Seattle, Washington

Cory Kepler

Education Specialist
Seattle Science Foundation
Seattle, Washington

Course Evaluation

Please take a moment to complete our online evaluation, which will be emailed to you. Your feedback helps to ensure the effectiveness of this CME activity, as well as improve future educational activities. All responses are considered anonymous. <https://www.surveymonkey.com/r/InnovativeBTM2022>

If you do not receive the survey via email, please call (206) 732-6500 or email cme@seattle-science-foundation.org.

Accreditation

Seattle Science Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™

Seattle Science Foundation designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Identifying and Resolving Conflicts of Interest

Purpose: The information provided addresses several requirements of the ACCME to help **ensure purpose** in CME activities. Everyone in a position to control the content of a CME activity must disclose all relevant financial relationships with commercial interests to the CME provider. This information must be disclosed to participants prior to the beginning of the activity. Also, CME providers must resolve current conflicts of interest prior to the educational activity.

Definitions: “Financial relationships” are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers’ bureau, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

The ACCME defines a **“commercial interest”** as any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. Among the exemptions to this definition are government organizations, non-health care related companies and non-profit organizations that do not advocate for commercial interests.

Circumstances create a **“conflict of interest”** when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

The ACCME defines **“relevant financial relationships”** as financial relationships in any amount occurring within the past 24 months that create a conflict of interest.

CME Activity Planning Committee Members: If a conflict of interest exists, the Planning Committee member must withdraw from the Planning Committee unless the conflict can be resolved. Resolution may be made by one of the following methods: (1) Peer review of CME content will be conducted at another oversight level to assure no commercial bias exists; (2) Change in focus of course so the activity does not include information related to products or services about which the planning committee member has a conflict; (3) Severing relationship(s) between the member and any related commercial interest; (4) Others to be determined by SSF CME Committee.

CME Activity Presenter: When a conflict of interest exists, the Planning Committee must address the conflict by one of the following methods: (1) Review content to be presented by speaker in advance to assure content balance; (2) Change topic so the presentation is not related to products or services where a conflict exists; (3) Select a different presenter without any related commercial interest; (4) Include presentations by other faculty to provide an overall balance to the content of the course; (5) Limit or specify the sources for recommendations that the presenter can use. Each speaker is required to give a balanced, evidence-based presentation based on published research. No conclusions or recommendations without external validation may be made by a speaker with a conflict of interest.

Faculty Disclosure Summary

The following planners and presenters, in the past 24 months, have/had a financial relationship with a commercial interest: (S = Speaker; P = Planner)

Howard Colman, M.D. (S): Consultant: Doctors/Teladoc, Orbus Therapeutics, Adastral Pharmaceuticals, Bristol Meyers Squibb

Lia Moriguchi Halasz, M.D. (S): Research: BioMimetic JV LLC

James Heath, Ph.D. (S): Scientific Advisory Board: Nanostring, Virtualitics, AtlasXomics; Boar Member: Isoplexis, PACT Pharma, Indi Molecular, BioAnalytica

Michael Lim, M.D. (S): Consultant: Tocagen VBI, InCephalo Therapeutics, Pyramid Bio, Merck, BMS, Isightec, Biohaven, Sanionia Hemispherian, Black Diamond, Therapeutics, Novocure, Noxxon; Research: Arbor, BMS, Accuray, Tocagen, Biohaven, Urogen; Stock Holder: Egret Therapeutics, Pyramid Bio; Royalties: Focused Radiation, Checkpoint Inhibitors Local Chemotherapy, Checkpoint Inhibitors Checkpoints for Neuro-Inflammation

Karis Schreck, M.D., Ph.D. (S): Honorarium: Springworks Therapeutics

Akanksha Sharma, M.D. (S): Speaker: Project Ronin; Grant Support: Chimerix

The following planners and presenters, in the past 24 months, have/had no financial relationship with a commercial interest: (S = Speaker; P = Planner)

Daniel Brown, M.D. (S); **Charles Cobbs, M.D.** (P, S); **Parvidner Hothi, Ph.D.** (S); **David Olayinka Kamson, M.D., Ph.D.** (S); **Zachary Litvack, M.D.** (P); **Joe Mendez, M.D.** (S); **Alon Orlev, M.D.** (P, S); **Kester Phillips, M.D.** (P,S); **Carlos Romo, M.D.** (S); **Matthew Smith-Cohn, DO** (P,S); **Linda Sahlin** (P); **Cory Kepler** (P)

All planners and presenters attested that their content suggestions and/or presentation(s) will provide a balanced view of therapeutic options and will be entirely free of promotional bias. All presentations have been reviewed by a planner with no conflicts of interest to ensure that the content is evidence-based and unbiased.